General Information of Drug (ID: DM0BT41)

Drug Name
NYX-458 Drug Info
Synonyms
Nevadistinel; YYL9TO6TW2; NEVADISTINEL [USAN]; SCHEMBL19850602; NYX-458; NYX-3054; HY-156626; CS-0886462; (4S)-2-[(4-Methoxyphenyl)methyl]-2,7-diazaspiro[3.5]nonane-1,6-dione; 2,7-Diazaspiro[3.5]nonane-1,6-dione, 2-[(4-methoxyphenyl)methyl]-, (4S)-; 2181816-92-0
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [1]
Cross-matching ID
PubChem CID
134241459
TTD Drug ID
DM0BT41

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Glutamic Acid DM4PUDW Schizophrenia 6A20 Approved [3]
Cycloserine DMT1I52 Bacterial infection 1A00-1C4Z Approved [4]
Benzphetamine DMIJATC Obesity 5B81 Approved [5]
Ketamine DMT5HA4 Anaesthesia 9A78.6 Approved [6]
Felbamate DM1V5ZS Epilepsy 8A60-8A68 Approved [7]
Memantine DMD9WSC Alzheimer disease 8A20 Approved [8]
Huperzine A DMMAWLU Alzheimer disease 8A20 Approved [9]
Levorphanol DMGS80V Pain MG30-MG3Z Approved [10]
Magnesium Sulfate DMVEK07 Acute pain MG31 Approved [11]
Magnesium DMU4ORS Ischemic stroke 8B11.5Z Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT04148391) A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia. U.S.National Institutes of Health.
2 NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. Mov Disord. 2020 Apr;35(4):640-649.
3 Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
4 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
5 Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
6 Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
7 Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
8 The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
9 Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
10 Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
11 Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
12 Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.